Grace Colón
CEO
IT
Inaya Therapeutics
Inaya Therapeutics develops novel therapeutic agents for rare cardiopulmonary diseases. The company focuses on addressing unmet medical needs through advanced drug discovery and development pipelines.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Sheila Gujrathi
Co-founder
Product
Problem
Patients with rare cardiopulmonary conditions often face limited treatment options and suboptimal outcomes due to a lack of innovative therapeutic development. This gap in the market leaves significant unmet medical needs unaddressed, impacting patient quality of life.
Solution
Inaya Therapeutics is dedicated to advancing the treatment paradigms for rare cardiopulmonary diseases through novel drug development. The company leverages its team's extensive experience in drug discovery and development, particularly within cardiopulmonary indications and advanced delivery modalities. By focusing on breakthrough therapies, Inaya aims to significantly improve patient outcomes and address critical unmet medical needs in this specialized therapeutic area.
Target Audience
The primary target audience includes patients and healthcare providers specializing in rare cardiopulmonary diseases, as well as pharmaceutical partners seeking to advance novel therapies.
Features
- Focus on developing novel therapeutic agents for rare cardiopulmonary conditions.
- Expertise in drug discovery and development pipelines.
- Experience with advanced drug delivery modalities.
- Commitment to addressing unmet medical needs in the cardiopulmonary space.